NCT01846117

Once-Daily Oral Dose of BeneFlax to Healthy Older Adults

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: University of Saskatchewan · Academic / Other
• Sex: All
• Age: 60 Years – 80 Years
• Healthy volunteers: Accepted

Summary

The investigators are investigating whether the flax lignan, secoisolariciresinol diglucoside, decreases oxidative stress and inflammation. The flax seed lignan is believed to be broken down in the body to produce the health benefits of flax. Flax lignan is separated from the whole flax seed as this compound is believed to have health effects. Decreasing oxidative stress and inflammation should improve a number of the problems associated with aging. This intervention consists of 600 milligrams of the flax lignan SDG daily or an equivalent amount of whey protein. The investigators are comparing lignan to a placebo (whey powder) to examine whether a dietary intervention (i.e. flax seed containing lignan) might decrease oxidative stress and inflammation.

Conditions

• Oxidative Stress
• Inflammation
• Aging
• Pain

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	secoisolariciresinol diglucoside, vitamin D	SDG supplementation as a packet of 1.6g/day of BeneFlax containing 600 mg SDG for 24 weeks Vitamin D Natural Product Number (NPN) 80003663 WN Pharmaceuticals Natural Factors Whey Factors

Timeline

• Start date: 2013-04-01
• Primary completion: 2014-11-01
• Completion: 2014-11-01
• First posted: 2013-05-03
• Last updated: 2018-06-14

Locations

1 site across 1 country: Canada